Hydroxyproline excretion has become a useful clinical index of collagen metabolism in man. Its significance is based on the fact that this amino acid, which is found in no other protein of the body except for a small amount present in elastin, comprises approximately 14% by weight of collagen.
Data on the excretion of hydroxyproline in man were first reported by Ziff et al. (1956) who found that normal adults excreted between 15 and 33 mg daily of this amino acid, almost completely in the form of peptide. Though no abnormality of hydroxyproline excretion was observed in patients with a variety of collagen diseases, markedly increased excretion was observed in normal growing children. Subsequently, Jasin et al. (1962) found that excretion was greatly decreased in a group of non-growing children with primary growth hormone deficiency, cretinism, and a number of other types of dwarfism. Restoration of growth with appropriate endocrine therapy produced a dramatic rise in hydroxyproline excretion.
Measurement of excretion in a patient with active acromegaly demonstrated markedly elevated excretion with levels as high as four times normal. Following irradiation of the pituitary, there was a slow fall in excretion, so that six months after irradiation the excretion had fallen to just above the upper limit of normal. When measured at the end of a year, the excretion remained at the upper limit of normal. A total of 4 patients with clinically active acromegaly have shown elevated levels of excretion, and 5 patients with inactive disease have all shown excretion at the upper limit of normal.
This evidence that hydroxyproline excretion was related to growth and growth hormone activity suggested that the excretion of this amino acid might be dependent on the turnover of soluble collagen, since this form of collagen is increased in the skin and bone of growing animals. Since the soluble collagen content of the connective tissue is also increased in animals with lathyrism, it was decided to study the effect of increased amounts of soluble collagen on excretion of hydroxyproline when the soluble collagen was generated by some process other than growth. Accordingly, the excretion of hydroxyproline peptides was determined in young rats rendered lathyritic by administration of aminopropionitrile . Increased excretion was, in fact, observed in comparison with paired controls. It was associated with an increased soluble collagen content in the skin when this was measured simultaneously. Thus, the evidence appears convincing that the amount of metabolically active soluble form of collagen in the body is important in the determination of the level of urinary hydroxyproline peptides.
Miscellaneous Clinical Studies
The impressive association of urinary hydroxyproline excretion with the metabolism of collagen has attracted the interest of investigators in examining a number of clinical conditions (Smiley & Ziff 1964) . Increased excretion has been noted in patients with Paget's disease, hyperparathyroidism with bone lesions, hyperthyroidism, Marfan's syndrome and following the administration of parathyroid extracts. It has also been observed in burn patients, individuals with Klinefelter's syndrome and some patients with very active scleroderma.
Concluding Remarks
Evidence indicates that the level of excretion of urinary hydroxyproline peptides reflects the metabolism of collagen and that processes such as growth, which accelerate collagen formation with concomitant increase in the metabolically active, extractable forms of collagen, are associated with increases in hydroxyproline peptide excretion.
In addition, collagen-degrading processes may result in increased levels of excretion. In those conditions such as hyperparathyroidism, Paget's disease, and even growth in which both synthesis and breakdown actively occur, it is difficult to make an evaluation of the relative contribution of the two processes to the urinary hydroxyproline. Excretion in the normal adult probably reflects the base-line contribution of mature collagen breakdown, but conditions increasing the soluble collagen fraction show an increase in urinary hydroxyproline excretion out of proportion to the actual mass of collagen this fraction represents. Whether this increment in excretion is a result of the high turnover rate of the soluble collagen pool alone, or whether it also reflects an increase in turnover of the mature collagen fractions is unknown at present. In spite of these questions, which remain to be clarified, urinary hydroxyproline excretion appears to provide a valuable index of collagen metabolism in the intact animal.
Meeting November 11 1964
Symposium on Gout The following papers were read:
Newer Concepts of Acute Gouty Arthritis Dr J E Seegmiller (Bethesda, Maryland, USA) see Arthritis & Rheumatism, 1965, 8, 714 Three Clinical Problems in Gout Dr 
